tbuckley/cabot-search huggingface dataset:
Elective surgery and the pill.
Journal: BMJ (1976)

whether it continues or not, is not without risks and dis- advantages for them.And it would do nothing but good for parents of adolescents to be reminded at intervals of the responsibility they have for the upbringing and welfare of their children.This may seem a formidable task, though not an impossible one if sufficient people care about adolescents, and especially about the nearly 5000 young schoolgirls each year in Britain who find themselves pregnant before they have much idea of what life has to offer.
Degree of diversity of hepatitis C virus quasispecies and progression of liver disease
Authors: M Honda
Journal: Hepatology (1994)

We examined the quasispecies of the hepatitis C virus genome in 28 patients with liver disease of varying severity. Nucleotide sequences of the hepatitis C virus genome spanning the region from the core to envelope were used to calculate the nucleotide diversity: 0.58% ± 0.88% in 5 patients with acute hepatitis, 0.85% ± 0.62% in 5 patients with chronic persistent hepatitis, 1.79% ± 0.92% in 11 patients with chronic active hepatitis, 3.05% ± 1.26% in 4 patients with cirrhosis and 2.71% ± 1.47% in 3 patients with cirrhosis complicated by hepatocellular carcinoma. Thus the intrapatient variation in nucleotides increased significantly with severity of liver disease (p < 0.01), except in those cases of cirrhosis complicated by hepatocellular carcinoma. Multivariate analysis including the histology, duration of infection, age, sex, history of blood transfusion and serum level of ALT at diagnosis as variables showed that the histological finding was the strongest independent factor of the nucleotide diversity (p = 0.003). Serial analysis of the genome in three patients demonstrated that the intrapatient variation in nucleotides increased with the progression of liver disease. The magnitude of the intrapatient variation in nucleotides deduced from the observed changes in the patients was correlated with the mean serum levels of ALT. These findings suggest that the degree of diversity of HCV quasispecies is related to the progression of liver disease. (Hepatology 1994;20:1144–1151.
Fellowships and Grants
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Fellowships and Grants Get access JNCI: Journal of the National Cancer Institute, Volume 83, Issue 19, 2 October 1991, Pages 1427–1428, https://doi.org/10.1093/jnci/83.19.1427 Published: 02 October 1991
PARIS
Journal: JAMA (1928)

<h3>A New Method of Sterilizing Cultures of Micro-Organisms</h3> Dr. Philibert, agrégé professor and head of microbiologic research at the Faculté de médecine de Paris, with the collaboration of MM. Courtier and Risler, heads of research departments at the Sorbonne, have discovered a method of sterilizing cultures of micro-organisms. A new electric lamp with very slender filaments of aluminum is employed. Under the action of a strong current, the filaments burn with a disruptive discharge and with volatilization of the aluminum. In this short space of time, radiations are produced that are more penetrative than ultraviolet rays and approach the penetration of roentgen rays. These radiations have a highly destructive action on cultures of micro-organisms. The staphylococcus is, destroyed in one twenty-fifth of a second, or 150 times more rapidly than with a mercury vapor lamp, which generates ultraviolet radiations of 3,500 candle power. Other micro-organisms besides the staphylococcus have been
RACE SUICIDE.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunologic Response and Factors Affecting Its Assessment
Authors: John A. Moore, Robert E. Faith
Journal: Environmental Health Perspectives (1976)

The potential harmful effects of toxic compounds on the developing immune system are discussed. This discussion is illustrated by results of studies of the effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the developing immune system of Fischer rats. While this compound and several others have been shown to have immunosuppressive effects, the available data do not support routine evaluation of the consequence of chemical exposure to the developing immune system.
Identification of highly expressed proteins: GRP78, HS7C and peptidyl-prolyl cis-trans-isomerase in enriched CD34+ stem cell fractions from cord blood using Proteomics technology
Authors: H. Lannert, V. Eckstein, T. Franz, A. Lenze, A. D. Ho
Journal: Journal of Clinical Oncology (2004)

9709 Background: Proteome analysis is a direct measurement of proteins in terms of their presence and relative abundance. The overall aim of a proteomic study is characterization of the complex network of cell regulation. Two or more different states of a cell can be compared and an attempt can be made to identify specific qualitative and quantitative protein changes. We focused our first proteom-investigations on CD34+ stem cells from cord blood (CB). Methods: Mononuclear cells were isolated by a standard Ficoll-Hypaque gradient separation method from PB. A Auto-MACS (Mylteni) and FACS Vantage SE cell sorter (Becton Dickinson) was used to highly enrich (>99%) CD34+ (116kD) cells fractions. Sample preparation, determination of protein concentrations, 2D-gel-electrophoresis with a 1D-separation isoelectric focusing (IEF) with Immobilised pH gradient (IPG) strips (17cm), 2D-separation with SDS-PAGE were performed and described in Proteome Works System (BioRad). After silver staining, imaging and image analysis was performed by BIO-RAD′s PDQuest 7.1-software. Sypro ruby staining was used to perform matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS). Results: 1.) The pattern of the CD34+ fraction from CB cells is complex and shows >1000 protein spots (dependent on protein concentration) in silver stain using PDQuest. 2.) The most dominant protein spots were characterized by MALDI-TOF analyses. GRP78 and HS7C (working as chaperones) and peptidyl-prolyl cis-trans-isomerase (involved in cell cycle, transcription) were identified. Conclusions: CD34+ cells from CB show a complex proteom with more than 1000 proteins. Proteomics is a highly effective method to describe the gen-expression of stem cells during their differentiation fate and to understand their cell biology characteristics. Further Proteom-comparisons with other subsets of stem cells from different origins (e.g. fetal liver, bone marrow) are currently performed. No significant financial relationships to disclose.
Moderated ePoster Session 4
Authors: Kkatarzyna Gil, A Pawlak, P Seweryniak, R Gil, L Balling, J Goetze, ; Rossing, ; Boesgaard, ; Gustafsson, Ssandra Van Wijk, ; Wijnen, ; Bekers, ; Tobler, ; Rickli, ; Erne, ; Rickenbacher, ; Me Pfisterer, ; Volders, ; Hp, Brunner-La Rocca
Journal: European Journal of Heart Failure (2014)
Correction
Journal: BMJ (1949)

BRITISH mortality rate may be fairly attributed to the absence of deaths from massive pulmonary embolism.It is likely, though not yet proved, that the administration of quinidine 3-5 gr.(0.2-0.32 g.) thrice daily for the first month may diminish the number of deaths from ventricular fibrillation.In other words, the combination of a low-calorie diet, anticoagulants, and quini- dine may be expected to halve the mortality rate of acute coronary thrombosis.In practice it is usual to limit anticoagulants to those cases in which thrombo-embolic complica-
Long-term treatment with recombinant interferon (IFN) alpha 2b of anti-HBE positive chronic hepatitis B: A randomized controlled trial Ist. Medicina Interna, Universita' degli Studi, Milano; *Ist. igiene e Medicina Preventiva, Ospedale Maggiore, Milano; **Ist. di Microbiologia, Ospedale Torrette, Ancona
Journal: Hepatology (1995)
Acromegaly
Authors: R. Reddy, S. Hope, J. Wass
Journal: BMJ (2010)

Acromegaly is a clinical disorder of adults characterised by changes in the face and extremities caused by excess growth hormone secretion. Growth hormone excess that occurs before fusion of the epiphyseal growth plates in a child or adolescent is called pituitary gigantism. In adults the excess growth hormone secretion is usually caused by a benign growth hormone secreting pituitary adenoma,1 though it may occasionally (in about 15% of cases) be part of a genetic condition, such as familial isolated pituitary adenoma, multiple endocrine neoplasia type 1, or McCune-Albright syndrome. #### Case scenario A 44 year old woman, known to have type 2 diabetes mellitus, presented with backache and a six month history of sweating, increased sleepiness, more recent headache, and decreased vision. She attributed her tight rings and numbness in the hands to arthritis. In view of the latter symptoms and her suggestive facial features, her general practitioner thought that acromegaly was a possibility, and requested growth hormone and insulin-like growth factor-1 (IGF-1) to be measured. Both tests showed raised values, so she referred the patient to an endocrine centre for further investigation, and the diagnosis was confirmed. #### How common is this condition?
Cancer—Attack or Retreat?
Authors: Peter P. Pekar
Journal: JAMA (1974)

AT THE SIGNING of the National Cancer Act of 1971, the President said: I hope that in the years ahead that we look back on this day and this action shown as being the most significant action taken during this administration. The present situation surrounding biomedical research is but a fleeting concept, when the continuing cancer developments are taken into account. Change is the order of the day—change in the "agri-business" industry, change in the US economy, change in biomedical research. The biomedical research industry stands at the threshold of a new era. Perhaps never before has the industry had, at the same time, so many problems and such bright prospects for the future. Excellent business planning, research, and management will be required to solve the problems and realize the prospects for the future. Actions taken by government and research institutions during the next few years will set the course
Sexual health of teenagers in England and Wales: analysis of national data
Journal: BMJ (1999)

Sexual health is an essential component of general health and includes the avoidance of unintended pregnancies and sexually transmitted infections.Unintended pregnancies are associated with increased risk of poor social, economic, and health outcomes for mother and child, 1 and important sequelae of sexually transmitted infections include pelvic inflammatory disease and infertility, cervical cancer, and increased susceptibility to HIV infection.For some of these factors teenagers are at greater risk than older women.
Phase I trial of yttrium 90 ibritumomab tiuxetan (<sup>90</sup>Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL)
Authors: L. J. Swinnen, I. W. Flinn, B. S. Kahl, E. Frey, K. Rogers, M. Jung, H. Jacene, R. L. Wahl
Journal: Journal of Clinical Oncology (2008)

8565 Background: 90Y-RIT dose escalation has been limited by hematopoetic toxicity. We conducted a phase I study of 90Y-RIT with ASCT, with radiation dose escalation based on patient-specific organ dosimetry. Methods: Eligible patients (pts.) had relapsed or refractory low-grade, mantle cell, or diffuse large cell NHL, age ≥18 yrs, platelet count ≥75K/mm3, WBC >3K/mm3, bone marrow involvement ≤35%, and acceptable renal and hepatic function. Pts. received rituximab 375 mg/m2 /wk x4, then one dose of cyclophosphamide 2.5 g/m2 with filgrastim 10 mcg/kg/d until stem cell collection. After collection of ≥2 x 106 CD34/kg, pts. received dosimetric (111In) ibritumomab tiuxetan on day 1 with quantitative planar and SPECT/CT scans, followed by the cohort specific dose of 90Y-RIT, determined by the continual re-assessment method (d10 = 10Gy and d90= 35Gy, first dose escalation= 18 Gy), on day 15. Stem cells were infused when estimated marrow dose rate was < 1 cGy/hr. Results: 24 pts. (14M:10F), median age 55, (44–70) with a median of 3 prior regimens were entered on study between 11/02 and 11/07. Six pts. failed to mobilize stem cells and did not receive 90Y-RIT. Histologies were: low grade (n=10), transformed (n=4), large B-cell NHL (n=1), and mantle cell NHL (n=3). 90Y-RIT was given at 0.4 mCi/kg (standard dose) in 3 pts.; then, based on SPECT-CT/hybrid dosimetry-predicted maximal liver radiation absorbed dose, in the following dose cohorts: 14–18 Gy = 5; 24 Gy= 6; 28 Gy = 3; 30.5 Gy = 1. The study was then closed due to lack of further drug. Of the 18 pts., 13 achieved CR (72%), 3 PR and 2 PD, at 60 days post-transplant. Median follow up is 20.3 mos (1.9–38.7 mos). All but 2 pts. have progressed; median time to progression (TTP) was 9 mos (0.1–40.2 mos) TTP did not differ among cohorts. Two pts. remain in CR at 38 and 2 mos. All patients engrafted rapidly. There was 1 treatment-related infectious death death; 1 pt. has developed MDS. No significant hepatotoxicity was seen. Conclusions: Patient-specific, organ-dosimetry based significant dose escalation with 90Y-RIT was achieved with outpatient ASCT support, MTD was not reached in this study. TTP did not appear to differ across 90Y-RIT dose cohorts. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Biogen Idec, Cell Therapeutics, GlaxoSmithKline Biogen Idec, Cell Therapeutics, Genentech, GlaxoSmithKline Biogen Idec, Cell Therapeutics, GlaxoSmithKline Biogen Idec, Cell Therapeutics, Genentech, GlaxoSmithKline Amgen, Biogen Idec, Cell Therapeutics, Genentech, GlaxoSmithKline
Ontogeny of the Barley Plant as Related to Mutation Expression and Detection of Pollen Mutations
Authors: A. L. Hodgdon, A. H. Marcus, P. Arenaz, J. L. Rosichan, T. P. Bogyo, R. A. Nilan
Journal: Environmental Health Perspectives (1981)

Clustering of mutant pollen grains in a population of normal pollen due to premeiotic mutational events complicates translating mutation frequencies into rates. Embryo ontogeny in barley will be described and used to illustrate the formation of such mutant clusters. The nature of the statistics for mutation frequency will be described from a study of the reversion frequencies of various waxy mutants in barley. Computer analysis by a "jackknife" method of the reversion frequencies of a waxy mutant treated with the mutagen sodium azide showed a significantly higher reversion frequency than untreated material. Problems of the computer analysis suggest a better experimental design for pollen mutation experiments. Preliminary work on computer modeling for pollen development and mutation will be described.
Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS)
Authors: K. Shitara, J. Tabernero, M. Dvorkin, W. Mansoor, H.-T. Arkenau, A. Prokharau, M. Alsina, M. Ghidini, C. Faustino, V. Gorbunova, E. Zhavrid, K. Nishikawa, A. Hosokawa, D. Ganea, Ş. Yalçın, K. Fujitani, G. Beretta, R. Winkler, T. Doi, D.H. Ilson
Journal: Annals of Oncology (2018)
Diverticulitis of the Colon: Recent Surgical Experiences
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I study of procaspase activating compound-1 (PAC-1) in the treatment of advanced malignancies.
Authors: Oana C. Danciu, Martin Kelly Nicholas, Rajyasree Emmadi, Hui Xie, Paul J. Hergenrother, Theodore M. Tarasow, Arkadiusz Z. Dudek
Journal: Journal of Clinical Oncology (2015)

TPS2607 Background: Members of the caspase family of cysteine proteases are key players in both the initiation and execution of apoptosis; the activation of procaspase-3 to caspase-3 is a critical event in the apoptotic cascade. Procaspase-3 levels are elevated in: glioblastoma, breast cancer, colon cancer, lung cancer, lymphoma, neuroblastoma, melanoma, and liver cancer. As a consequence, caspase-3 levels are abnormally low in these tumors, allowing the tumors to avoid apoptosis. PAC-1 is a small molecule that activates procaspase-3 and induces apoptosis of cancer cells in culture. PAC-1 showed efficacy across a wide range of cancer cell lines, as well as in animal models of cancer, including brain cancer. This novel compound potently synergizes with chemotherapy agents (e.g.doxorubicin, temozolomide, etoposide, carboplatin). Methods: This is a Phase I dose escalation study with a modified- Fibonacci 3+3 design, consisting of two parts: to determine the maximum tolerated dose (MTD) of PAC-1 in advanced malignancies, and to determine the MTD of PAC-1 when combined with temozolomide in patients with primary brain tumors. For both parts the MTD dose level will expand to a total of 9 patients to ensure safety. Primary objectives: establish MTD, tolerability and toxicity. Secondary and correlative objectives: pharmacokinetics, pharmacodynamics, preliminary antitumor activity correlation with procaspase-3 expression in tumor, clinical response and adverse effects. Neurological symptoms of CNS toxicity will be assessed throughout the trial. Inclusion criteria: diagnoses of advanced malignancies (for part 1) and high grade glioma (for part 2), ECOG PS 0-2, adequate organ function. Exclusion criteria: received prior cytotoxic therapy in the last 3-6 weeks (duration based on prior therapy) or uncontrolled chronic illness. Administration and design: Part 1, PAC-1 (PO) will be dosed at 75-450 mg daily (up to 5 dose levels) on days 1-21 on 28 days cycle. In Part 2, the first PAC-1 dose will be 1 dose lower than the PAC-1 MTD established in Part 1 (up to 3 dose levels).Temozolomide (PO) will be dosed at 150 mg/m2 daily for 5 days starting on day 8 of each cycle. The study is open to enrollment. Clinical trial information: NCT02355535.
BELGIUM
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The status and future of small maternity services in Iowa
Authors: H. A. Hein
Journal: JAMA (1986)

Small Iowa community hospitals (fewer than 500 deliveries annually) are currently the site of approximately 37% of hospital births in the state. Many of these facilities face severe financial constraints aggravated by reduced Medicare payments and diagnosis-related group payment mechanisms. The quality and quantity of services provided by small hospitals are illustrated by birth and mortality data for the period that spans the development of Iowa's regionalized perinatal care system. Small hospitals appear to compare very favorably when matched with their larger level I counterparts with regard to neonatal mortality rates, incidence of births of very-low-birth-weight neonates, survival of very-low-birth-weight neonates, occurrence of neonatal deaths relative to the total birth population, and incidence of neonatal morbidities. Because these hospitals provide valuable services in Iowa's perinatal care system, their closure may seriously compromise perinatal health care for rural lowans. (<i>JAMA</i>1986;255:1899-1903)
Upper abdominal pain--an unusual symptom of ectopic pregnancy
Authors: M. L. Collins
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal